2022版欧洲肿瘤内科学会免疫治疗毒性管理指南解读

A prospective of the 2022 European Society of Medical Oncology clinical practice guideline for the management of toxicities from immunotherapy

以免疫检查点抑制剂为代表的肿瘤免疫治疗为肿瘤治疗领域带来了巨大的成功。随着免疫治疗应用患者人群的迅速扩充,免疫相关不良事件也得到了越来越普遍的报道,免疫治疗毒性的管理也愈发成为肿瘤临床诊治的重点问题。时隔5年后,欧洲肿瘤内科学会发布了第2版免疫治疗毒性管理指南,对现有证据进行了梳理和更新。本文基于新版指南内容并结合临床实践,对2022版指南的亮点、不足之处以及理念上的转变予以讨论。

Cancer immunotherapy,represented by immune checkpoint inhibitor,has brought a huge success to the field of cancer therapy.With the rapid expansion of the population of patients treated with immunotherapy,immune-related adverse events have been more and more commonly reported,and the optimized management of immunotherapy toxicities has become a key question in the field of clinical oncology.Five years later in 2022,the European Society of Medical Oncology published the second edition of the guideline for the management of toxicities from immunotherapy,which updates and summarizes the current evidence.Based on the materials of the guideline and our clinical experiences,this article discusses the highlights,shortcomings,and conceptual changes of this updated guideline.